Clinical trials: Chronic Rhinosinusitis (CRS) With and Without Nasal Polyps
Chronic Rhinosinusitis (CRS) With and Without Nasal Polyps
Safety and Efficacy of BHV-3000 (Rimegepant) Orally Disintegrating Tablet for the Acute Treatment of Chronic Rhinosinusitis
The purpose of this study is to compare the efficacy and safety of rimegepant versus placebo in the acute treatment of chronic rhinosinusitis (CRS) with and without nasal polyps.
- Trial name
- NCT05248997
- Testing
- rimegepant 75 mg ODT
- Where
- 33 sites in United States
- Volunteers
- 261 people
- Sponsor
- Pfizer